

# Petra M Nederlof

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3524950/publications.pdf>

Version: 2024-02-01

40  
papers

3,080  
citations

218677

26  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

5104  
citing authors

#	ARTICLE	IF	CITATIONS
1	BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. <i>Nature</i> , 2011, 477, 179-184.	27.8	403
2	Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. <i>Nature Genetics</i> , 2000, 26, 291-299.	21.4	335
3	Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. <i>Cancer Research</i> , 2003, 63, 1449-53.	0.9	233
4	<i>In situ</i> hybridisation with fluoresceinated DNA. <i>Nucleic Acids Research</i> , 1991, 19, 3237-3241.	14.5	196
5	Analysis of PALB2/FANCN-associated breast cancer families. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 6788-6793.	7.1	192
6	Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR. <i>PLoS ONE</i> , 2011, 6, e17791.	2.5	166
7	High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer. <i>Cancer Research</i> , 2009, 69, 3625-3633.	0.9	142
8	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 479-489.	2.5	124
9	Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. <i>Cancer Research</i> , 2002, 62, 7110-7.	0.9	123
10	Detection of chromosome aberrations in interphase tumor nuclei by nonradioactive <i>in situ</i> hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1989, 42, 87-98.	1.0	114
11	Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. <i>Cancer Research</i> , 2005, 65, 822-7.	0.9	97
12	Pulmonary Squamous Cell Carcinoma following Head and Neck Squamous Cell Carcinoma: Metastasis or Second Primary?. <i>Clinical Cancer Research</i> , 2005, 11, 6608-6614.	7.0	87
13	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. <i>Breast Cancer Research</i> , 2014, 16, R47.	5.0	86
14	Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. <i>Modern Pathology</i> , 2009, 22, 223-231.	5.5	74
15	Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2010, 16, 651-663.	7.0	61
16	Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 71-81.	2.8	53
17	Functional <i>Ex Vivo</i> Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. <i>Clinical Cancer Research</i> , 2018, 24, 6277-6287.	7.0	53
18	Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 379-389.	2.5	47

#	ARTICLE	IF	CITATIONS
19	Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. <i>European Journal of Human Genetics</i> , 2008, 16, 820-832.	2.8	42
20	Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. <i>Blood</i> , 2003, 102, 324-327.	1.4	40
21	Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 99-108.	2.5	36
22	Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 538-546.	3.4	29
23	Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. <i>Molecular Oncology</i> , 2015, 9, 1274-1286.	4.6	29
24	Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling. <i>PLoS ONE</i> , 2013, 8, e55734.	2.5	29
25	Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2010, 17, 686-693.	1.5	28
26	Proteasome: from structure to function. <i>Current Opinion in Biotechnology</i> , 1996, 7, 376-385.	6.6	26
27	Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 544-551.	2.8	25
28	Estrogen receptor $\beta$ yields treatment-specific enhancers between morphologically similar endometrial tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E1316-E1325.	7.1	25
29	Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 673-680.	2.8	24
30	Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 317-327.	2.5	20
31	BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency. <i>Clinical Cancer Research</i> , 2017, 23, 1236-1241.	7.0	19
32	Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 699-710.	2.8	17
33	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	7.0	17
34	Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21q22 as a putative breast cancer susceptibility locus. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 947-956.	2.8	16
35	Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. <i>Molecular Oncology</i> , 2015, 9, 877-888.	4.6	16
36	Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study. <i>BMC Cancer</i> , 2016, 16, 811.	2.6	13

#	ARTICLE	IF	CITATIONS
37	Oncogenesis and classification of mixed-type liposarcoma: A radiological, histopathological and molecular biological analysis. <i>International Journal of Cancer</i> , 2011, 128, 778-786.	5.1	11
38	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 1401-1409.	6.4	11
39	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. <i>Npj Breast Cancer</i> , 2022, 8, 60.	5.2	11
40	Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	7.0	9